Wells Fargo lowered the firm’s price target on Elevance Health (ELV) to $495 from $593 and keeps an Overweight rating on the shares. Following the bulk of earnings, the firm is updating models and detailed earnings bridges for each large cap MCO. Wells is not incorporating any election-related changes to its valuation framework at this time.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance sues U.S. over Medicare star ratings, Bloomberg says
- Molina Healthcare price target raised to $345 from $335 at Stephens
- Medicare paid insurers approx $4.2B for home diagnoses, WSJ reports
- 3 Best Stocks to Buy Now, 10/24/2024, According to Top Analysts
- Elevance Health price target lowered to $551 from $643 at Morgan Stanley